With its innovative technology BioPredictive provides these new non-invasive tests:

• FibroTest-ActiTest® is the combination of FibroTest® & ActiTest®;
• FibroMAX® is the combination of up to five non-invasive liver tests: FibroTest®, ActiTest®, SteatoTest®, NashTest® and AshTest®.

 
The BioPredictive breakthrough technology uses an algorithm based on the patients’ gender, age, weight, height and specifi c blood biomarkers*. These algorithms have been scientifically validated and quality-monitored to ensure that the results delivered are of the highest analytical standards. The validation and analytical standardization of FibroTest-ActiTest® and FibroMAX® have been established in over 50 clinical studies.

These non-invasive biomarkers now provide new clinical options for the diagnosis of most common and chronic liver diseases, especially as a good alternative or complement to the traditional liver biopsy.  

FibroTest and FibroMax provide precise and instant diagnostic results.

• FibroTest-ActiTest®

• FibroTest® : diagnoses hepatic fibrosis
• ActiTest® : assesses viral necro-infl ammatory activity

• FibroMAX®
  

• FibroTest® : diagnoses hepatic fi brosis
• SteatoTest® : diagnoses hepatic steatosis (otherwise known as ‘fatty liver’)
  • the most common cause of ALT and GGT abnormalities
• ActiTest® : assesses viral necro-infl ammatory activity
• AshTest® : diagnoses severe alcoholic steatohepatitis (ASH) in excessive drinkers
• NashTest® : diagnoses non-alcoholic steatohepatitis (NASH) in patients who are overweight, insulin resistant, have diabetes or hyperlipidemia.

 
The FibroTest biomarkers are:

• alpha-2 macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT and ALT.

 
The FibroMax biomarkers are:

• alpha-2 macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, ALT, AST, GGT, fasting glucose, triglycerides, and total cholesterol.

 
 
Your Patients’ Best Alternative to a Liver Biopsy !